Trials / Completed
CompletedNCT05649462
Effect of Vitamin D Supplementation on Vedolizumab Response in Patients With Ulcerative Colitis
Retrospective Analysis of the Effect of Vitamin D Supplementation on the Clinical Efficacy of Vedelizumab in Ulcerative Colitis Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 80 (actual)
- Sponsor
- Second Affiliated Hospital of Wenzhou Medical University · Academic / Other
- Sex
- All
- Age
- 15 Years – 65 Years
- Healthy volunteers
- —
Summary
It is uncertain whether vitD3 supplementation is beneficial for the remission of ulcerative colitis (UC). The effects of vitD3 supplements on the efficacy of vidrecizumab in Chinese UC patients were retrospectively analyzed. Methods: Patients with moderate to severe UC were recorded. These patients were initially treated with VDZ. VitD3 supplementation was defined as 400IU/d vitD3 supplementation during the first infusion of VDZ and continued throughout the follow-up period. Disease activity was assessed using the modified Mayo score.
Conditions
Timeline
- Start date
- 2020-01-01
- Primary completion
- 2021-11-01
- Completion
- 2022-06-01
- First posted
- 2022-12-14
- Last updated
- 2022-12-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05649462. Inclusion in this directory is not an endorsement.